Determination of the antibacterial activity of simvastatin against periodontal pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: An in vitro study

Contemporary Clinical Dentistry

Volumn 5, Issue 3, 2014, Pages 377-382

  Emani, Shilpa ^a   Gunjiganur, Gayathri V ^a   Mehta, Dhoom Singh ^a  

^a Davangere   (India)

Author keywords

Actinobacillus actinomycetemcomitans; minimum inhibitory concentration; Porphyromonas gingivalis; simvastatin

Indexed keywords

EID: 84978920067     PISSN: 0976237X     EISSN: 09762361     Source Type: Journal    
DOI: 10.4103/0976-237X.137959     Document Type: Article

References (42)

1. Baehni P, Tsai CC, McArthur WP, Hammond BF, Taichman NS. Interaction of inflammatory cells and oral microorganisms. VIII. Detection of leukotoxic activity of a plaque-derived gram-negative microorganism. Infect Immun 1979;24:233-43
2. Lamont RJ, Oda D, Persson RE, Persson GR. Interaction of Porphyromonas gingivalis with gingival epithelial cells maintained in culture. Oral Microbiol Immunol 1992;7:364-7
3. Rudney JD, Chen R, Sedgewick GJ. Intracellular Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in buccal epithelial cells collected from human subjects. Infect Immun 2001;69:2700-7
4. van Winkelhoff AJ, Rams TE, Slots J. Systemic antibiotic therapy in periodontics. Periodontol 2000 1996;10:45-78
5. Slots J, Rams TE. Antibiotics in periodontal therapy: Advantages and disadvantages. J Clin Periodontol 1990;17:479-93
6. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48 Suppl 1:5-16
7. Mombelli A. The use of antibiotics in periodontal therapy. In: Lindhe J, Karring T, Lang NP, editors. Clinical Periodontology and Implant Dentistry. UK: Munksgaard; 2003. p. 106-49
8. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. BMJ 1993;306:688-91
9. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000;71:1554-60
10. Grover HS, Luthra S, Maroo S, Maroo N. The pleotropic role of statins: Could it be the imminent host modulation agent in periodontics? Dent Res J (Isfahan) 2013;10:143-8
11. Bergman P, Linde C, Pütsep K, Pohanka A, Normark S, Henriques-Normark B, et al. Studies on the antibacterial effects of statins-in vitro and in vivo. PLoS One 2011;6:e24394
12. Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z. Antibacterial activity of statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob 2012;11:13
13. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008;61:362-4
14. Shivanand S, Kumar AP, Jagadevappa P. Influence of method of preparation on solubility, physicochemical properties and in-vitro release profile of simvastatin-cyclodextrin inclusion complexes: A comparative study. Int J Chem Tech Res 2010;2:562-71
15. Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: A randomized clinical trial. J Periodontol 2010;81:214-22
16. Song W, Condron S, Mocca BT, Veit SJ, Hill D, Abbas A, et al. Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-treated mice. Vaccine 2008;26:5741-51
17. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clin Infect Dis 2009;49:1749-55
18. Haynes WG, Stanford C. Periodontal disease and atherosclerosis: From dental to arterial plaque. Arterioscler Thromb Vasc Biol 2003;23:1309-11
19. Fiehn NE, Larsen T, Christiansen N, Holmstrup P, Schroeder TV. Identification of periodontal pathogens in atherosclerotic vessels. J Periodontol 2005;76:731-6
20. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol 1996;67:1123-37
21. Arbes SJ Jr, Slade GD, Beck JD. Association between extent of periodontal attachment loss and self-reported history of heart attack: An analysis of NHANES III data. J Dent Res 1999;78:1777-82
22. Khlgatian M, Nassar H, Chou HH, Gibson FC 3rd, Genco CA. Fimbria-dependent activation of cell adhesion molecule expression in Porphyromonas gingivalis-infected endothelial cells. Infect Immun 2002;70:257-67
23. Herzberg MC, Meyer MW. Effects of oral flora on platelets: Possible consequences in cardiovascular disease. J Periodontol 1996;67:1138-42
24. Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, et al. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 2005;25:1446-51
25. Johansson A, Kalfas S. Virulence mechanisms of leukotoxin from Aggregatibacter actinomycetemcomitans. In: Oral Health Care: Prosthodontics, Periodontology, Biology, Research and Systemic Conditions. Zagreb: InTech; 2012. p. 165-92
26. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 2000;3:303-11
27. Heitz-Mayfield LJ, Schätzle M, Löe H, Bürgin W, Anerud A, Boysen H, et al. Clinical course of chronic periodontitis. II. Incidence, characteristics and time of occurrence of the initial periodontal lesion. J Clin Periodontol 2003;30:902-8
28. Ramesh A, Thomas B, Rao A. Evaluation of the association between chronic periodontitis and acute coronary syndrome: A case control study. J Indian Soc Periodontol 2013;17:210-3
29. Sreedevi K, Rao JV, Fareedullah MD, Vijayakumar S. A study on prescription pattern of statins in cardiovascular disease. Der Pharm Lettre 2011;3:393-6
30. Stancu C, Sima A. Statins: Mechanism of action and effects. J Cell Mol Med 2001;5:378-87
31. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-8
32. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85:1137-42
33. Elavarasu S, Suthanthiran TK, Naveen D. Statins: A new era in local drug delivery. J Pharm Bioallied Sci 2012;4:S248-51
34. Rao SK, Prasad T, Mohanta GP, Manna PK. An overview of statins as hypolipidemic drugs. Int J Pharm Sci Drug Res 2011;3:178-83
35. Neu HC. Current practices in antimicrobial dosing. Rev Infect Dis 1981;3:12-8
36. Lindy O, Suomalainen K, Mäkelä M, Lindy S. Statin use is associated with fewer periodontal lesions: A retrospective study. BMC Oral Health 2008;8:16
37. Cunha-Cruz J, Saver B, Maupome G, Hujoel PP. Statin use and tooth loss in chronic periodontitis patients. J Periodontol 2006;77:1061-6
38. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70
39. Medeiros BV, Azevedo IM, Rego AC, Filho IA, Ferreira MC, Medeiros CA. Attenuation of lung injury using simvastatin in a rat sepsis model. J Surg Clin Res 2012;3:1-8
40. Chaudhry MZ, Wang JH, Blankson S, Redmond HP. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt) 2008;9:183-94
41. Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 2004;18:451-65, vii
42. Briethaupt H. The new antibiotics: Can nivel antibacterial treatment combat the rising tide of drug resistant infections? Nat Biotechnol 1999;17:1165-9